Virology

EQS-News: Immunic to Participate in Investor and Scientific Conferences in March

Retrieved on: 
Wednesday, March 13, 2024
Virology, Biotechnology, Society, Conference, Doctor of Philosophy, Abstract, Poster, Communication, Medicinal chemistry, Pharmaceutical industry

NEW YORK, March 7, 2024 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in March:

Key Points: 
  • NEW YORK, March 7, 2024 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in March:
    March 11-13: Leerink Partners Global Biopharma Conference.
  • Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic, and Jessica Breu, Vice President Investor Relations and Communications, will participate in one-on-one investor meetings at this conference in Miami, FL.
  • Two abstracts have been accepted for poster presentations at this conference in Munich, Germany.
  • The poster presentations will be accessible on the “Events and Presentations” section of Immunic’s website at: https://ir.imux.com/events-and-presentations .

Arbutus to Participate in Two Upcoming Investor Conferences

Retrieved on: 
Friday, March 8, 2024
Arbutus, Barclays, Virology, Webcast, CFBV, Conference

WARMINSTER, Pa., March 08, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Arbutus management team will participate in and host one-on-one meetings at the following two upcoming investor conferences which are being held in Miami, FL:

Key Points: 
  • WARMINSTER, Pa., March 08, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Arbutus management team will participate in and host one-on-one meetings at the following two upcoming investor conferences which are being held in Miami, FL:
    Barclays 26th Annual Global Healthcare Conference: Formal Presentation on March 12, 2024 at 2:05 pm ET
    Jefferies Biotech on the Bay Summit: March 13, 2024
    To access the live webcast of the presentation at the Barclays 26th Annual Global Healthcare Conference please visit: https://investor.arbutusbio.com/events-presentations .
  • An archived replay of the webcast will be available on the Arbutus website for a limited time after the event.

Bioxytran Announces Preprint of Shingles Case Study Showing Clearance Using a Topical Galectin-3 Antagonist

Retrieved on: 
Wednesday, March 6, 2024
Woman, Virology, ResearchGate, Preprint, Pain, Dermatology, Regression, Viral, Vaccine, Shingles, SOC, Research, Randomized controlled trial

BOSTON, MASSACHUSETTS, March 06, 2024 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral diseases, announced today the preprint in ResearchGate entitled “Association of Rapid Shingles Lesion Clearance and Regression of Herpes Zoster Neuralgia in Case Study Using Topical Galectin-3 Antagonism” showed a time lapsed clearance of the shingles lesions using a topical Galectin-3 antagonist. Vaccines have been developed to prevent shingles, but there are few effective antiviral therapies capable of treating the outbreak while reducing the pain associated with the condition. The case study demonstrated a rapid response in the reduction of pain the size of the lesion area, due to a galectin antagonist.

Key Points: 
  • BOSTON, MASSACHUSETTS, March 06, 2024 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. ( BIXT ), (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral diseases, announced today the preprint in ResearchGate entitled “Association of Rapid Shingles Lesion Clearance and Regression of Herpes Zoster Neuralgia in Case Study Using Topical Galectin-3 Antagonism” showed a time lapsed clearance of the shingles lesions using a topical Galectin-3 antagonist.
  • Vaccines have been developed to prevent shingles, but there are few effective antiviral therapies capable of treating the outbreak while reducing the pain associated with the condition.
  • The case study demonstrated a rapid response in the reduction of pain the size of the lesion area, due to a galectin antagonist.
  • “This case study constitutes a proof of concept of the benefit of using a galectin antagonist in human shingles infection.

Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, February 29, 2024
LNP, HBV, Court, PD, Research, Virology, Expert witness, CFBV, AASLD, Construction, Nivolumab, Investment, Arbutus, HBsAg, EASL, Vaccine, Interim, Safety, COVID-19, Pharmacokinetics, Roivant Sciences, Patient, Clinical trial, Congress, RNA interference, DNA, Pharmaceutical industry

Arbutus plans to announce end-of-treatment data from this trial in the first half of 2024.

Key Points: 
  • Arbutus plans to announce end-of-treatment data from this trial in the first half of 2024.
  • Arbutus plans to announce end-of-treatment data from this portion of the trial in the first half of 2024.
  • Arbutus is advancing AB-101 into part two of this clinical trial which involves dosing healthy subjects with multiple-ascending doses of AB-101.
  • Roivant Sciences Ltd. owned approximately 23% of the Company’s outstanding common shares as of December 31, 2023.

Dyadic Announces Strategic Partnership Agreement to Develop Affordable Rabies Prophylactics and Vaccines Using its Proprietary C1 Cell Microbial Protein Production Platform

Retrieved on: 
Wednesday, February 28, 2024
Incidence, Virology, LMIC, Vaccine, C1, SME, European, Dyadic, COVID-19, Innovation, Rabies, AVATAR, Disease, DRS, Research, Partnership

The aim is to develop highly efficacious, scalable, and affordable rabies prophylactics and vaccines utilizing Dyadic's C1 protein production platform.

Key Points: 
  • The aim is to develop highly efficacious, scalable, and affordable rabies prophylactics and vaccines utilizing Dyadic's C1 protein production platform.
  • This collaboration seeks to address the global burden of rabies, a disease that annually claims tens of thousands of lives.
  • As per the strategic partnership agreement, Dyadic will receive an equity stake in, fully funded research and development costs, and specified product milestones and royalties upon commercialization.
  • Punt highlighted the potential of combining advances in vaccinology with Dyadic's C1 protein production platform to accelerate research, enhance product development, and lower manufacturing costs.

Bioxytran’s Oral Antiviral Drug to Enter Dose Optimization Clinical Trial for COVID-19

Retrieved on: 
Wednesday, February 21, 2024
OTCQB, RSV, Virology, Nuclear magnetic resonance, Viral, Vaccine, Lower respiratory tract infection, University, COVID-19, Virus, Patient, Clinical trial, Molar, Carbohydrate, Mutation, Research

BOSTON, MASSACHUSETTS, Feb. 21, 2024 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT), (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral diseases, announced that the first patients have been treated with ProLectin-M in its dose optimization trial. ProLectin-M is intended to become a first line treatment for standard risk COVID-19 patients, but based on the broad-spectrum in vitro discovery could easily expand to upper respiratory tract infections. Following this dose optimization trial, Bioxytran intends to use the trial data to inform the design of the Phase 3 registrational trial in India, while also adhering to the FDA’s request for additional data.

Key Points: 
  • Following this dose optimization trial, Bioxytran intends to use the trial data to inform the design of the Phase 3 registrational trial in India, while also adhering to the FDA’s request for additional data.
  • The multi-center clinical trial in India will be a randomized double-blind placebo-controlled trial and is set to enroll 40 patients.
  • “After we complete the dose optimization trial, the next regulatory milestone is a registrational trial,” said Dr. Leslie Ajayi, Bioxytran’s medical director.
  • “We are on the cusp of completing a clinical trial of standard risk patient that contracted COVID-19.

Enanta Pharmaceuticals to Participate at Leerink Partners Global Biopharma Conference

Retrieved on: 
Wednesday, March 6, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Immunology, Medication, Virology, Webcast, Conference

Enanta Pharmaceuticals, Inc .

Key Points: 
  • Enanta Pharmaceuticals, Inc .
  • (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for indications in virology and immunology, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, and Tara L. Kieffer, Ph.D., Chief Product Strategy Officer, will participate in a fireside chat at Leerink Partners Global Biopharma Conference on March 13, 2024 at 10:40 a.m.
  • A live webcast of the event will be accessible by visiting the “Events and Presentations” section on the “Investors” page of Enanta’s website at www.enanta.com .
  • A replay of the webcast will be available following the presentation and will be archived for at least 30 days.

NIAID-Sponsored Study Shows N-803 Combined with Neutralizing Antibodies Could Lead to Sustained HIV Viral Control After Discontinuation of Antiretroviral Therapy

Retrieved on: 
Wednesday, March 6, 2024
Pharmaceutical, AIDS, Health, Clinical Trials, Infection, Bangladesh Technical Education Board, SHIV, AD8, Research, Virology, BCG, NIAID, FDA, Safety, Animal, Hook effect, NMIBC, Rockefeller University, ART, Viremia, Patient, NK, Harvard Medical School, HIV, HIV/AIDS, Immune system, Vaccine

Treatment with N-803 and bNAbs led to immune activation and transient viremia, but only limited reductions in the SHIV reservoir.

Key Points: 
  • Treatment with N-803 and bNAbs led to immune activation and transient viremia, but only limited reductions in the SHIV reservoir.
  • Upon ART discontinuation, all animals experienced viral rebound, followed by long-term virus control for up to 10 months in approximately 70% of those treated with N-803 and bNAbs.
  • “When combined with broadly neutralizing antibodies, N-803 has the potential to provide viral control without significant reduction in the viral reservoir, which further suggests that the complete eradication of this reservoir may not be required to induce sustained remission after discontinuing antiretroviral therapy."
  • Safety and efficacy have not been established by any Health Authority or Agency, including the FDA.

Gilead to Present Late-Breaking Data and Real-World Evidence Highlighting Innovative Antiviral Portfolio and Research Pipeline at CROI 2024

Retrieved on: 
Monday, February 26, 2024
Biotechnology, FDA, AIDS, Health, Pharmaceutical, Research, Infectious Diseases, Hospitals, Science, COVID-19, Clinical Trials, Senior, Hepatitis B, CROI, Hook effect, RWE, STR, Viral, Virus, DTG, Mortality, Lenacapavir, Hepatitis, HBV, Vesatolimod, Fungal infection, HIV-1, MDR, PWH, HDV, Boxed warning, European, Islatravir, Tablet, European Commission, Liver disease, Omicron, Conference, Safety, ART, Civil service commission, Abstract, Bictegravir, Natural history, Virology, Emtricitabine, Gilead Sciences, MD, Food, Coinfection, Immunodeficiency, European Economic Area, Risk, Prevalence, Dexamethasone, Patient, Tuberculosis, INSIGHT, HIV, Pharmaceutical industry

Outcomes from pipeline research studies will also provide insights into investigational treatment candidates, including the novel combination regimen of lenacapavir plus bictegravir.

Key Points: 
  • Outcomes from pipeline research studies will also provide insights into investigational treatment candidates, including the novel combination regimen of lenacapavir plus bictegravir.
  • Additionally, a late-breaker oral presentation of Week 24 data from the INSIGHT trial evaluating Biktarvy in people with HIV and tuberculosis will be presented.
  • Gilead will present new data evaluating the safety and efficacy of Hepcludex® (bulevirtide) in people living with the coinfections of HIV, hepatitis B (HBV) and hepatitis delta (HDV).
  • Biktarvy combines the novel, unboosted INSTI bictegravir, with the Descovy® (emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, F/TAF) backbone.

Immunic to Participate in Investor and Scientific Conferences in March

Retrieved on: 
Thursday, March 7, 2024
Virology, Biotechnology, Conference, Society, Doctor of Philosophy, Abstract, Poster, Communication, Medicinal chemistry, Pharmaceutical industry

Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic, and Jessica Breu, Vice President Investor Relations and Communications, will participate in one-on-one investor meetings at this conference in Miami, FL.

Key Points: 
  • Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic, and Jessica Breu, Vice President Investor Relations and Communications, will participate in one-on-one investor meetings at this conference in Miami, FL.
  • Two abstracts have been accepted for poster presentations at this conference in Munich, Germany.
  • The poster presentations will be accessible on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations .
  • Two abstracts have been accepted for poster and oral presentations at this conference in Vienna, Austria.